Table 2 Targeted therapeutic strategies of ENO1 in various tumors
Drug | Mechanisms of Action | Cancer Type | Biological Functions | References |
|---|---|---|---|---|
AP-III-a4 (ENOblock) | Nonsubstrate analog inhibitor | Colorectal cancer | Cell proliferation, tumor growth | [53] |
Gastric cancer | Cell stemness, glycolysis, chemoresistance | [58] | ||
Breast cancer | Radiosensitivity | [35] | ||
HuL227 | Antibody | Prostate cancer | Tumor growth, monocyte recruitment, angiogenesis | [56] |
Anti-ENO1 antibody | Antibody | Gastric cancer, non-small cell lung cancer | Chemoresistance | [125] |
Ag85B-ENO146-82 | DNA vaccine | Lewis lung cancer | Tumor growth, immune response | [132] |
ENO1 DNA vaccine | DNA vaccine | Pancreatic cancer | Immune response, survival of tumor bearing mice | [133] |
POMHEX | Substrate-competitive inhibitor | ENO1-deleted glioblastoma | Cell viability | [134] |
Curcumin | Downregulation of ENO1 expression | Glioblastoma | Glycolysis, migration, invasion, apoptosis | [18] |
Downregulation of ENO1 expression | Triple-negative breast cancer | Glycolysis | [135] | |
Cinnamaldehyde | Downregulation of ENO1 expression | Melanoma | Tumor growth, apoptosis, glycolysis, cell cycle | |
Covalent conjugation | Hepatocellular carcinoma | Glycolysis, TCA cycle | [138] | |
ISL-NLs | Downregulation of ENO1 expression | Colorectal cancer | Glycolysis | [139] |
Salidroside | Downregulation of ENO1 expression | Gastric cancer | Glycolysis, cell proliferation | [140] |
Aspirin | Post-translational modifications | Hepatocellular carcinoma | Glycolysis, cell proliferation, tumorigenesis | |
Macrosphelide A | Specific binding | Liver cancer, leukaemia, breast cancer | cell proliferation, apoptosis | [142] |
Metformin | Promoting ubiquitination | Gastric cancer | cell proliferation, EMT | [66] |
Melatonin | Downregulation of ENO1 expression | Bladder cancer | Glycolysis, tumorigenesis, chemoresistance | [143] |
Triterpenoids | Colorectal cancer | Glycolysis, cell proliferation, apoptosis | [144] |